계명대학교 의학도서관 Repository

A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients

Metadata Downloads
Author(s)
Hyung Joon KimJu Hyun KimJong Eun YeonYeon Seok SeoJeong Won JangYong Kyun ChoByoung Kuk JangByung Hoon HanChanghyeong LeeJoon Hyeok LeeJung-Hwan YoonKang Mo KimMoon Young KimDo Young KimNeung Hwa ParkEun Young ChoJune Sung LeeJin-Woo LeeIn Hee KimByung-Cheol SongByung-Seok LeeOh Sang Kwon
Keimyung Author(s)
Jang, Byoung Kuk
Department
Dept. of Internal Medicine (내과학)
Journal Title
J Korean Med Sci
Issued Date
2022
Volume
37
Issue
11
Keyword
TenofovirHepatitis B, ChronicHepatitis B VirusEfficacySafety
Abstract
Background:
Tenofovir disoproxil fumarate (TDF, Viread®) had been used as a standard treatment option of chronic hepatitis B (CHB). This clinical trial was conducted to evaluate the efficacy and safety of DA-2802 (tenofovir disoproxil orotate) compared to TDF.

Methods:
The present study was a double blind randomized controlled trial. Patients with CHB were recruited from 25 hospitals in Korea and given DA-2802 at a dose of 319 mg once daily or Viread® at a dose of 300 mg once daily for 48 weeks from March 2017 to January 2019. Change in hepatitis B virus (HBV) DNA level at week 48 after dosing compared to baseline was the primary efficacy endpoint. Secondary efficacy endpoints were proportions of subjects with undetectable HBV DNA, those with normal alanine aminotransferase (ALT) levels, and those with loss of hepatitis B envelop antigen (HBeAg), those with loss of hepatitis B surface antigen (HBsAg). Adverse events (AEs) were also investigated.

Results:
A total of 122 patients (DA-2802 group: n = 61, Viread® group: n = 61) were used as full analysis set for efficacy analysis. Mean age, proportion of males, laboratory results and virologic characteristics were not different between the two groups. The change in HBV DNA level at week 48 from baseline was −5.13 ± 1.40 in the DA-2802 group and −4.97 ± 1.40 log10 copies/mL in the Viread® group. The analysis of primary endpoint using the nonparametric analysis of covariance showed statistically significant results (P < 0.001), which confirmed non-inferiority of DA-2802 to Viread® by a prespecified noninferiority margin of 1. The proportion of undetectable HBV DNA was 78.7% in the DA-2802 group and 75.4% in the Viread® group (P = 0.698). The proportion of subjects who had normal ALT levels was 75.4% in the DA-2802 group and 73.3% in the Viread® group (P = 0.795). The proportion of those with HBeAg loss was 8.1% in the DA-2802 group and 10.8% in the Viread® group (P = 1.000). No subject showed HBsAg loss. The frequency of AEs during treatment was similar between the two groups. Most AEs were mild to moderate in severity.

Conclusion:
DA-2802 is considered an effective and safe treatment for patients with CHB.
Keimyung Author(s)(Kor)
장병국
Publisher
School of Medicine (의과대학)
Citation
Hyung Joon Kim et al. (2022). A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients. J Korean Med Sci, 37(11), e92. doi: 10.3346/jkms.2022.37.e92
Type
Article
ISSN
1598-6357
Source
https://jkms.org/search.php?where=aview&id=10.3346/jkms.2022.37.e92&code=0063JKMS&vmode=FULL
DOI
10.3346/jkms.2022.37.e92
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/44080
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.